Search

Dredging activities produce large amounts of polluted sediments that require adequate management strategies. Sediment reuse and relocation can involve several environmental issues, such as the release of CO 2 and nitrogen compounds in the environment, the transfer of metals to plant tissues and the persistence of phytotoxic compounds. In this framework, the aim of the present work is to evaluate the use of biochar at different doses, in combination with plant growth, to reduce the environmental impacts polluted dredged sediments. Irrespective to the plant treatment, the amendment of the sediment with the lowest dose of biochar (3%) reduced by 25% the CO 2 emissions of the substrate, by 89% the substrate carbon loss and by 35% the amount of nitrogen released into the environment (average values of the three plant treatments). The negative priming effect of biochar on organic matter mineralization can be responsible for the beneficial reduction of carbon and nitrogen release in the environment. The lack of similar effects observed at the higher biochar doses can depend on the low albedo of the biochar particles, causing the substrate warming (+1 °C for highest biochar dose) and accelerating the organic matter mineralization. Finally, shrub growth in combination with 3% biochar was able to offset the CO 2 emission of the sediment and to reduce the amount of nitrogen lost. This work provides new insight on the potential benefit related to the biochar amendment of organic matter-rich dredged sediments, suggesting that the use of moderate dose of wood biochar in combination with shrub plantation can reduce the release of CO 2 and nitrogen compounds in the environment., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.)

Background: Idiopathic pulmonary fibrosis (IPF) is a complex disease with a highly variable clinical course and generally poor prognosis. Classified as a rare disease, significant increases in incidence have been recorded worldwide in recent years. Left untreated IPF is extremely debilitating with substantial personal, social and economic implications., Objectives: To discuss how IPF is diagnosed and managed in real life clinical practice with particular reference to Italy and to determine how new and effective therapies can be incorporated into a patient-centred management approach in order to improve the lives of patients with IPF., Outcomes: Barriers to early diagnosis are discussed. Cited reasons for delays in diagnosing IPF in Italy include: inherent difficulties in diagnosis; lack of knowledge/awareness of the condition among point-of-contact healthcare professionals; delays in referral to centres of excellence and underestimation of symptoms by both patients and healthcare workers. Valid therapeutic options with demonstrated efficacy in slowing the decline in lung function are now available for patients with IPF. The ASCEND trial confirmed the effects of pirfenidone, approved for the treatment of IPF on the basis of the four phase III trials. Nintedanib, a tyrosine kinase inhibitor that targets the PDGF receptors α/β, FGF receptors 1 to 3, and VEGF receptors 1-3, is approved in the USA and the EU for the treatment of IPF. The TOMORROW and the INPULSIS placebo controlled trials in patients with IPF confirm the efficacy and safety of nintedanib and recent interim analyses endorse its long-term effects in slowing disease progression., Conclusions: The importance of early and accurate diagnosis of IPF cannot be underestimated and it is the duty of all healthcare professionals to be vigilant to the symptoms of IPF and to involve a multidisciplinary team in diagnosing and managing IPF early in the course of disease., (Copyright © 2017 Elsevier Ltd. All rights reserved.)